Community Research and Development Information Service - CORDIS

H2020

ONCOCHECK Report Summary

Project ID: 738707

Periodic Reporting for period 1 - ONCOCHECK (A simple blood test for prognosis and monitoring of patients undergoing cancer therapy.)

Reporting period: 2017-01-01 to 2017-12-31

Summary of the context and overall objectives of the project

ONCOCHECK’s main objective is to prove the clinical value of telomere-associated variables (TAVs) as biomarkers for cancer management. The project is divided in a series of clinical studies including hematological and solid tumors in adults and children.
In the new era of personalized medicine cancer management needs better diagnostic, prognostic and monitoring tools. Doctors need to be able to make earlier and more accurate decisions that can help to improve cancer patient individual´s management. Integrating telomere associated variables in cancer care will lead to improved outcomes.
In oncology screening false positive and false negatives are misleading, other times there is no clear mean to predict who is going to have a more aggressive form of the disease or which patients will respond to therapy. Clinical data and the accuracy of current screening tools will be enhanced with TAVs, by an easy blood test performed at diagnostic and then at each routine check-up to anticipate disease progression. Patient´s TAVS profile could indicate who will benefit from specific treatments. In fact, less invasive procedures for early detection will save payers and improve patient´s quality of life while providing powerful tools to guide physicians during cancer follow up and helping to give the right drug to the right person.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

In the first 12 months of the project we have received all Ethics approval for the different clinical studies. Electronic notebooks -according to protocol designs, were created and all sites were initiated.
Steady recruitment in the first half of the year increased significantly after the summer with more than 2000 samples processed to the date.
The initial data analyses on discreet groups of patients from the different studies indicate the significance of TAVs in patients versus control individuals. Machine learning with the interim data will follow.
A dedicated webpage and brand registration for ONCOCHECK were created as active platforms to disseminate our work. Communication has been reinforced with abstract presented to oncology international meetings, business development at BIO-specific conferences, press releases and webinars as well as social media activities; blogs and tweets.
Revalidation of Life Length as Medical Laboratory (CLIA, ISO15189, A2LA and Spanish Health Ministry) was successfully achieved in 2017, granting the quality of the clinical development of TAVs as oncology biomarkers.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The ONCOCHECK test can be categorized as a new tool for the in vitro diagnostic/monitoring of cancer - in particular it can be included within the cellular health screening market. Global Industry Analysis in this sector forecast and steady demand for biomarkers and a clear tendency for the use of combination of biomarkers as cancer is no longer seen as a single disease; each patient is unique in the onset, evolution and response to treatment.
The ability to position telomere associated variables (TAV) in the Next Generation Cancer Diagnostics Market will bring a unique set of Molecular diagnostics techniques that will offer a more sustainable and effective way for disease diagnosis, prognosis and monitoring.
The use of analytically validated technologies and clinical monitoring to produce data of the highest quality will allow us to perform machine learning protocols that would, ultimately, return algorithms to guide doctors on their clinical oncology practice. The simplicity of the test (i.e.: blood samples vs. imaging technology) will result in significant savings for the payers and improved clinical outcomes.

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top